Literature DB >> 16499424

[Ophtalmoscopic examination in critically ill non-neutropenic patients: Candida endophtalmitis].

Eugenio Pérez Blázquez1.   

Abstract

Invasive Candida (IC) infection is the most common cause of endogenous endophthalmitis. Ocular candidiasis develops within three days and at least two weeks of fungemia. There are two characteristic ocular signs: Candida chorioretinitis defined as retina and choroid lesions without vitreal involvement, and Candida endophthalmitis defined as chorioretinitis with extension into the vitreous with characteristic fluffy balls. The most common initial visual symptoms are blurred vision and floaters. Amphotericin B, fluconazole and voriconazole are effective in the treatment of chorioretinitis; however, when vitreous is involved vitrectomy seems necessary. Early antifungal systemic treatment at first evidence of infection in patients at risk of IC, appears to decrease dramatically the incidence of endogenous fungal endophthalmitis, probably healing minimal chorioretinal infections. Routine ophthalmoscopic examination seems of little value in patients with positive blood culture, with early implementation of antifungal treatment, without symptoms of ocular infection and without impairment of the level of consciousness during the episode. However, periodic ophthalmoscopic examination should be performed in children with candidemia and critically ill patients with documented deep Candida infection.

Entities:  

Mesh:

Year:  2006        PMID: 16499424     DOI: 10.1016/s1130-1406(06)70006-7

Source DB:  PubMed          Journal:  Rev Iberoam Micol        ISSN: 1130-1406            Impact factor:   1.044


  2 in total

Review 1.  Invasive candidiasis in pediatric intensive care units.

Authors:  Sunit Singhi; Akash Deep
Journal:  Indian J Pediatr       Date:  2009-11-12       Impact factor: 1.967

Review 2.  Etiological agents of fungal endophthalmitis: diagnosis and management.

Authors:  Rubens C Vilela; Luiza Vilela; Priscila Vilela; Raquel Vilela; Roberta Motta; Ana Paula Pôssa; Cirênio de Almeida; Leonel Mendoza
Journal:  Int Ophthalmol       Date:  2013-10-01       Impact factor: 2.031

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.